Tricaprilin (Trioctanoin) is used in study for patients with mild to moderate Alzheimer's disease and has a role as an anticonvulsant and a plant metabolite[1]. Administration of the tricaprylin emulsion, or even tricaprylin alone, significantly ameliorated the anti-GBM (anti-glomerular basement membrane) antibody-induced renal dysfunction in these rats[2]. The stability was higher for the microcapsules with tricaprylin as the oily phase than for the microcapsules with oleic acid. The higher stability of the microcapsules with tricaprylin would be ascribed to the lower partition coefficient of PTSA (1,3,6,8-pyrenetetrasulfonic acid tetrasodium salt) to the oily phase[3]. The change in plasma acetoacetate, β-hydroxybutyrate and total ketones was highest after C8 (tricaprylin) (0.5 to 3 h post-dose) and was lower during tests in which octanoate was absent or was diluted by C10 (tricaprin) in the test oil. C8 was about three times more ketogenic than C10 and about six times more ketogenic than C12 under these acute metabolic test conditions, an effect related to the post-dose increase in octanoate in plasma total lipids[4].
搜索
